Positron emission tomography (PET) and magnetic resonance imaging (MRI) for assessing tumour resectability in advanced epithelial ovarian, fallopian tube and/or primary peritoneal cancer
Referencias
Additional references
Baker TR, Piver MS, Hempling RE. Long term survival by cytoreductive surgery to less than 1 cm, induction weekly cisplatin and monthly cisplatin, doxorubicin, and cyclophosphamide therapy in advanced ovarian adenocarcinoma. Cancer 1994;74(2):656‐63. [PUBMED: 8033045]
Beynon R, Leeflang MM, McDonald S, Eisinga A, Mitchell RL, Whiting P, et al. Search strategies to identify diagnostic accuracy studies in MEDLINE and EMBASE. Cochrane Database of Systematic Reviews 2013, Issue 9. [DOI: 10.1002/14651858.MR000022.pub3]
Borley J, Wilhelm‐Benartzi C, Yazbek J, Williamson R, Bharwani N, Stewart V, et al. Radiological predictors of cytoreductive outcomes in patients with advanced ovarian cancer. British Journal of Obstetrics and Gynaecology 2015;122(6):843‐9.
Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Montz FJ. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta‐analysis. Journal of Clinical Oncology 2002;20(5):1248‐59.
Deeks JJ, Bossuyt PM, Gatsonis C (editors). Cochrane Handbook for Systematic Reviews of Diagnostic Test Accuracy Version 1.0.0. Available from: http://srdta.cochrane.org/. The Cochrane Collaboration, 2013.
du Bois A, Reuss A, Pujade‐Lauraine E, Harter P, Ray‐Coquard I, Pfisterer J. Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO‐OVAR) and the Groupe d'Investigateurs Nationaux Pour les Etudes des Cancers de l'Ovaire (GINECO). Cancer 2009;115(6):1234‐44. [PUBMED: 19189349]
Earle CC, Schrag D, Neville BA, Yabroff KR, Topor M, Fahey A, et al. Effect of surgeon specialty on processes of care and outcomes for ovarian cancer patients. Journal of the National Cancer Institute 2006;98(3):172‐80.
Elattar A, Bryant A, Winter‐Roach BA, Hatem M, Naik R. Optimal primary surgical treatment for advanced epithelial ovarian cancer. Cochrane Database of Systematic Reviews 2011, Issue 8. [DOI: 10.1002/14651858.CD007565.pub2]
Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, et al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11. International Agency for Research on Cancer; Lyon, France: Available from: http://globocan.iarc.fr, accessed on 27/5/20152013.
Kehoe S, Hook J, Nankivell M, Jayson GC, Kitchener H, Lopes T, et al. Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open‐label, randomised, controlled, non‐inferiority trial. Lancet 2015;386(9990):249‐57.
Macaskill P, Gatsonis C, Deeks JJ, Harbord RM, Takwoingi Y. Chapter 10: Analysing and Presenting Results. In: Deeks JJ, Bossuyt PM, Gatsonis C editor(s). Cochrane Handbook for Systematic Reviews of Diagnostic Test Accuracy. 1.0. The Cochrane Collaboration, 2010.
Mercado C, Zingmond D, Karlan BY, Sekaris E, Gross J, Maggard‐Gibbons M, et al. Quality of care in advanced ovarian cancer: the importance of provider specialty. Gynecologic Oncology 2010;117(1):18‐22.
Morrison J, Haldar K, Kehoe S, Lawrie TA. Chemotherapy versus surgery for initial treatment in advanced ovarian epithelial cancer. Cochrane Database of Systematic Reviews 2012, Issue 8. [DOI: 10.1002/14651858.CD005343.pub3]
Mutch DG, Prat J. 2014 FIGO staging for ovarian, fallopian tube and peritoneal cancer. Gynecologic Oncology 2014;133(3):401‐4.
National Cancer Institute (Bethesda, MD, USA). PDQ® Ovarian Epithelial, Fallopian Tube, and Primary Peritoneal Cancer Treatment. Available at: http://www.cancer.gov/types/ovarian/hp/ovarian‐epithelial‐treatment‐pdq: Date last modified March 27, 2015. Accessed June 8th 2015.
National Institute for Health and Clinical Excellence (NICE). Ovarian cancer: The recognition and initial management of ovarian cancer. https://www.nice.org.uk/guidance/CG122/2011.
Olson SH, Mignone L, Nakraseive C, Caputo TA, Barakat RR, Harlap S. Symptoms of ovarian cancer. Obstetrics and Gynecology 2001;98(2):212‐7.
Prat J, FIGO Committee on Gynecologic Oncology. Staging classification for cancer of the ovary, fallopian tube, and peritoneum. International Journal of Gynaecology and Obstetrics 2014;124(1):1‐5.
Reitsma JB, Glas AS, Rutjes AW, Scholten RJ, Bossuyt PM, Zwinderman AH. Bivariate analysis of sensitivity and specificity produces informative summary measures in diagnostic reviews. Journal of Clinical Epidemiology 2005;58(10):982‐90. [PUBMED: 16168343]
The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan) [Computer program]. Version 5.3. The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
Roett MA, Evans P. Ovarian cancer: an overview. American Family Physician 2009 Sep;80(6):609‐16.
Rutten MJ, Gaarenstroom KN, Van Gorp T, van Meurs HS, Arts HJ, Bossuyt PM, et al. Laparoscopy to predict the result of primary cytoreductive surgery in advanced ovarian cancer patients (LapOvCa‐trial): a multicentre randomized controlled study. BMC Cancer 2012;12:31.
Rutten MJ, Leeflang MM, Kenter GG, Mol BW, Buist M. Laparoscopy for diagnosing resectability of disease in patients with advanced ovarian cancer. Cochrane Database of Systematic Reviews 2014, Issue 2. [DOI: 10.1002/14651858.CD009786.pub2]
Rutter CM, Gatsonis CA. Regression methods for meta‐analysis of diagnostic test data. Academic Radiology 1995;2(S1):S48‐S56.
Rutter CM, Gatsonis CA. A hierarchical regression approach to meta‐analysis of diagnostic test accuracy evaluations. Statistical Methodology 2001;20:2865‐84.
Schrag D, Earle C, Xu F, Panageas KS, Yabroff KR, Bristow RE, et al. Associations between hospital and surgeon procedure volumes and patient outcomes after ovarian cancer resection. Journal of the National Cancer Institute 2006;98(3):163‐71.
Schünemann HJ, Oxman AD, Brozek J, Glasziou P, Jaeschke R, Vist GE, et al. GRADE: grading quality of evidence and strength of recommendations for diagnostic tests and strategies. BMJ 2008;336:1106‐10.
Suidan RS, Ramirez PT, Sarasohn DM, Teitcher JB, Mironov S, Iyer RB, et al. A multicenter prospective trial evaluating the ability of preoperative computed tomography scan and serum CA‐125 to predict suboptimal cytoreduction at primary debulking surgery for advanced ovarian, fallopian tube, and peritoneal cancer. Gynecologic Oncology 2014;134(3):455‐61.
van Enst WA, Ochodo E, Scholten RJ, Hooft L, Leeflang MM. Investigation of publication bias in meta‐analyses of diagnostic test accuracy: a meta‐epidemiological study. BMC Medical Research Methodology 2014;14:70. [DOI: 10.1186/1471‐2288‐14‐70; PUBMED: 24884381]
Vergote I, van Gorp T, Amant F, Leunen K, Neven P, Berteloot P. Timing of debulking surgery in advanced ovarian cancer. International Journal of Gynecological Cancer 2008;18(suppl 1):11‐9.
Vergote I, Tropé CG, Amant F, Kristensen GB, Ehlen T, Johnson N, et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. New England Journal of Medicine 2010;363(10):943‐53.
Whiting PF, Rutjes AW, Westwood ME, Mallett S, Deeks JJ, Reitsma JB, et al. QUADAS‐2 Group. QUADAS‐2: a revised tool for the quality assessment of diagnostic accuracy studies. Annals of Internal Medicine 2011;18(155):529‐36.
Figuras y tablas -
Figure 1
Definitions of the two by two table, wherein the index tests are tabulated against the reference standard outcome, on the analysis: macroscopic debulking versus incomplete debulking with residual disease of any size (i.e. consisting of deposits ≤ 1 cm and > 1 cm in diameter ). TP= true positive, FP= false positive, FN= false negative, TN=true negative.
Figuras y tablas -
Figure 2
Definitions of the two by two table, wherein the index tests are tabulated against the reference standard outcome, on the analysis: macroscopic debulking or incomplete debulking with residual disease ≤ 1 cm in diameter versus incomplete resection with residual disease > 1 cm in diameter. TP= true positive, FP= false positive, FN= false negative, TN=true negative.
